Skip to main content
. 2021 Oct 1;13(10):1597. doi: 10.3390/pharmaceutics13101597

Figure 3.

Figure 3

Stabilization and release of modified CXCL12. (A) Truncation of native CXCL12 wt by MMP9 and (B) for the [S4V]-stabilized compound 4 with MMP9 (0.2 ng/µL), investigated by MALDI-ToF MS analysis. (C) Release from coated PCL-co-LC scaffolds upon MMP9 incubation of compound 4. Half-time of release and the rate constant k are given in the corresponding table. Data are shown as mean ± SEM, n ≥ 2. Significance is displayed as *** = p ≤ 0.001. (D) Migration of Jurkat cells in a Transwell migration assay towards gradients of in situ released compound 4 by action of MMP9 from PCL-co-LC scaffolds vs. supernatants from non-releasable compound 3. The data are expressed as mean ± SD, n = 3. Significance is displayed as * = p ≤ 0.05 compared to uncoated scaffolds.